A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)

• Main Authors: Jie Zhou (Author), Jinping Zhang (Author), Qiaoyun Wang (Author), Miaoxin Peng (Author), Yun Qian (Author), Fang Wu (Author), Qi Rao (Author), Laji DanZhen (Author), Yonggong Yang (Author), Siliang Wang (Author), Mengying Liu (Author)
• Format: Book
• Published: SAGE Publishing, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objectives: This pharmacovigilance analysis was conducted to assess the safety signals of FMS-related tyrosine kinase 3 (FLT3) inhibitors in a real-world setting using the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Design: We analyzed adverse event (AE) report...